5 Years After Hachmo: What Happened to HBOT's Telomere Promise

The 2020 paper that launched a longevity movement

In November 2020, Hachmo et al. published a prospective trial in the journal Aging that electrified the longevity world. Thirty-five healthy adults over age 64 underwent 60 daily HBOT sessions at 2.0 ATA over 90 days. The result:

• Telomere length in peripheral blood mononuclear cells increased 20-38%, depending on cell type
• Senescent T cell populations decreased approximately 37%
• No change in lifestyle, diet, or medication

Telomeres — the protective caps on chromosome ends that shorten with each cell division and are correlated with biological aging — had been reversed, apparently without any pharmaceutical intervention. The paper was covered extensively in mainstream media. Longevity influencers and biohackers embraced it. A commercial clinical infrastructure (Aviv Clinics) rapidly scaled around the finding.

What the paper actually showed — and did not

Hachmo et al. were themselves careful about the limitations:

• No control group — the comparison was within-subject, before vs. after HBOT. There was no sham-HBOT or no-treatment comparator.
• Small sample — 35 participants, single centre
• Surrogate endpoint — telomere length is a biomarker of cellular aging, not a hard clinical outcome
• Durability unclear — the follow-up window after the last HBOT session was 1-2 weeks. Whether the telomere gains persist months or years later remains uncharacterised
• Telomerase activity was not directly measured, so the mechanism by which telomeres lengthened could not be definitively identified

These are the authors' own cautions. Media coverage largely did not reproduce them.

Five years later: no replication

In the half-decade since Hachmo 2020, the specific telomere finding has not been independently replicated in a peer-reviewed study. This is a notable absence given the paper's commercial and cultural impact.

Several reasons likely contribute:

1. Trial cost — a replication would require a full 60-session HBOT course in a comparable aged cohort, with controls. This is a significant resource commitment that academic funders have not prioritised.
2. Replication incentives — longevity research funding tends to favor novel findings over replication. The commercial beneficiaries of the original finding have no incentive to fund potentially-null replications.
3. Design complexity — a true replication would need to control for the possibility that any intensive 90-day intervention (daily medical appointments, lifestyle changes, Hawthorne effect) could affect senescence markers.
4. Interim mechanism research — some researchers may have deprioritised telomere outcomes in favor of more direct clinical endpoints (cognitive function, physical performance) in HBOT longevity studies.

What has happened instead: Aviv Clinics

In the absence of replication science, a commercial infrastructure has rapidly scaled. Aviv Clinics — Efrati-affiliated and licensing the Hachmo-era research — now operates in Florida and Dubai, delivering a proprietary 12-week program that combines HBOT with cognitive training, physical training, and nutritional coaching. Over 1,000 individuals have reportedly completed the program.

Aviv does not sell HBOT as a direct telomere intervention; the program is positioned around cognitive performance, physical performance, and "healthy aging." But the Hachmo paper is central to the marketing narrative and commercial legitimacy.

Internal outcome tracking at Aviv presumably exists but has not translated into additional peer-reviewed telomere data.

The mechanism remains plausible

Nothing about the five-year gap is evidence that the original finding is wrong. The underlying mechanism — HBOT-induced reactive oxygen species → HIF-1α stabilisation → possible telomerase activation and senescent-cell clearance — is biologically coherent. The hyperoxic-hypoxic paradox framework (Hadanny & Efrati 2020, Biomolecules) provides theoretical grounding.

What is missing is the clinical confirmation that the telomere observation translates into durable, meaningful anti-aging benefit at the organism level. Telomere length is a biomarker, not an outcome. Patients do not care whether their PBMC telomeres are 20% longer; they care whether they live longer, cognitively sharper, and physically more capable. The connection between the biomarker and those endpoints is not yet established.

What this means for patients considering HBOT for longevity

Honest framing matters here. The evidence is:

• One suggestive but methodologically limited trial
• Zero independent peer-reviewed replication after five years
• Biologically plausible mechanism
• Growing commercial sector operating in advance of definitive science
• Excellent safety profile at the doses studied

If you have the discretionary budget and are willing to treat the therapy as experimental, HBOT at the Efrati-protocol dose is low-risk. Realistic expectations: do not expect clinically meaningful lifespan extension based on current evidence. Any benefit — if real — may well be real, but the magnitude is uncharacterised.

For HBOT indications with stronger evidence (long COVID, TBI, chronic wounds, radiation injury), see our conditions overview and studies database. For the full anti-aging evidence summary, see our anti-aging page.

What the field needs

A proper replication study — ideally a multi-centre RCT with sham control, standardised telomere measurement, and 6-12 month post-treatment follow-up — would substantially clarify where HBOT sits in longevity medicine. Without it, Hachmo 2020 remains an interesting but singular data point, and the gap between the science and the commercial narrative continues to widen.